Outcomes of a single center's initial experience with the Penuma® penile implant.

OBJECTIVES: To provide new data, techniques, and safety and efficacy outcomes in patients undergoing Penuma® penile implant surgery at a large tertiary care center. METHODS: We performed a retrospective analysis of men undergoing Penuma® implants between November 2020 and January 2022 with a single surgeon at a tertiary hospital. Measurements of penile length were made both pre- and post-operatively. Adverse events including infection and unsatisfactory cosmetic outcomes requiring revision were recorded. We also provide detailed technique descriptions of Penuma® implantation and revision. Outcomes include measurements of incidents of peri and post-operative adverse events and penile length and girth pre- and post-operatively. RESULTS: 49 male patients underwent Penuma® implant surgery. Mean age was 40.2 ± 8.9 years. Mean BMI was 28.2 ± 4.5. All but two patients were non-smokers and only two had comorbidities (diabetes). Pre-operative mean flaccid length was 8.1 ± 1.9 cm. Post-operative mean length was 12.3 ± 1.9 cm. Patients added an average of 4.9 ± 2.9 cm to their penile length, a 52% increase (p < 0.01). Average follow up time was 6 months. Among the complications were 1 case of infection and 2 cases of erosion. There were 4 cases of persistent flaring of the Penuma®; three required revision surgery, all with a good cosmetic outcome. CONCLUSION: The Penuma® implant can be used to safely enhance flaccid penile length and girth in patients with retractile penis or other cosmetic deformities. Should complications occur, they are mainly cosmetic and can be easily corrected with low risk.